Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack A Roth

Showing results (321-330 of 337) with videos related to

Pageof 34
Sort By:
Cancer Discovery|July 8, 2024
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung CancerHaniel A Araujo, Ximo Pechuan-Jorge, Teng Zhou, et al.
Cancer Cell|January 22, 2021
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilitiesCarl M Gay, C Allison Stewart, Elizabeth M Park, et al.
Molecular Cancer Therapeutics|April 19, 2024
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus RecommendationsFunda Meric-Bernstam, Michael W Lloyd, Soner Koc, et al.
Science (New York, N.Y.)|September 7, 2023
Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitorsXiangdong Lv, Xuan Lu, Jin Cao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2019
The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine CarcinomaMinglei Zhuo, Yanfang Guan, Xue Yang, et al.
Journal for Immunotherapy of Cancer|August 11, 2021
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancerMarcelo V Negrao, Ferdinandos Skoulidis, Meagan Montesion, et al.
Nature Communications|May 3, 2024
Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancerFranziska Haderk, Yu-Ting Chou, Lauren Cech, et al.
Journal for Immunotherapy of Cancer|October 24, 2024
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancerNicolas Zhou, Cheuk H Leung, William N William, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapyStephen G Swisher, Jack A Roth, Ritsuko Komaki, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 12, 2020
Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLCLingzhi Hong, Marcelo V Negrao, Seyedeh S Dibaj, et al.
Pageof 34

Showing results (321-330 of 337) with videos related to

Sort By:
Pageof 34
Cancer Discovery|July 8, 2024
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung CancerHaniel A Araujo, Ximo Pechuan-Jorge, Teng Zhou, et al.
Cancer Cell|January 22, 2021
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilitiesCarl M Gay, C Allison Stewart, Elizabeth M Park, et al.
Molecular Cancer Therapeutics|April 19, 2024
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus RecommendationsFunda Meric-Bernstam, Michael W Lloyd, Soner Koc, et al.
Science (New York, N.Y.)|September 7, 2023
Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitorsXiangdong Lv, Xuan Lu, Jin Cao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2019
The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine CarcinomaMinglei Zhuo, Yanfang Guan, Xue Yang, et al.
Journal for Immunotherapy of Cancer|August 11, 2021
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancerMarcelo V Negrao, Ferdinandos Skoulidis, Meagan Montesion, et al.
Nature Communications|May 3, 2024
Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancerFranziska Haderk, Yu-Ting Chou, Lauren Cech, et al.
Journal for Immunotherapy of Cancer|October 24, 2024
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancerNicolas Zhou, Cheuk H Leung, William N William, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapyStephen G Swisher, Jack A Roth, Ritsuko Komaki, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 12, 2020
Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLCLingzhi Hong, Marcelo V Negrao, Seyedeh S Dibaj, et al.
Pageof 34